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Brain metastases are a significant cause
of morbidity and mortality among
oncologic patients, affecting 20-40%
of this population.1 Several therapeutic
strategies for intracranial metastases
exist, including stereotactic radiosurgery
(SRS), whole brain radiotherapy (WBRT),
surgical resection and supportive care
with steroids, though systemic therapy
remains an option for patients with
selected cancers.2 WBRT was historically
the treatment modality of choice for
brain metastases with or without surgical
resection.3,4 Technological improvements
in Gamma Knife and LINAC-based SRS
coupled with data indicating decreased
cognitive toxicity with SRS5, have led to
increased utilization of SRS6. Although
evidence-based clinical practice guidelines exist for the use of SRS for brain
metastases,7-12 there are comparatively
fewer reports that study specific aspects
of SRS plan evaluation or if current
use reflects the recommendations of
professional societies. In that context,
the current study represents one of the
few national surveys which specifically
investigates these issues to clarify the
role of SRS for intracranial metastases in
clinical practice.
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ABSTRACT
Background: Stereotactic radiosurgery (SRS) has emerged as an important modality for
the treatment of intracranial metastases. There are currently few established guidelines
delineating indications for SRS use and fewer still regarding plan evaluation in the treatment of multiple brain metastases.
Methods: An 18 question electronic survey was distributed to radiation oncologists
at National Cancer Institute (NCI) designated cancer centers in the US (60). Centers
without radiation oncologists were excluded. Physicians who indicated that they do
not prescribe SRS were excluded from the remaining survey questions. Sign test and
Chi-square test were used to determine if responses differed significantly from random
distribution.
Results: 116 of the 697 radiation oncologists surveyed completed the questionnaire,
representing 51 institutions. 62% reported treating patients with brain metastases using
SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung
(49.3%) malignancies. SRS was used more frequently for <10 brain metastases (73.7%;
p<.0001) and whole brain radiation therapy (WBRT) for >10 brain metastases (82.5%;
p<.0001). The maximum number of lesions physicians were willing to treat with SRS
without WBRT was 1-4 (40.4%) and 5-10 (42.4%) (p<.0001 compared to 11-15, 16-20
and no limit). The most important criteria for choosing SRS or WBRT were number of
lesions (p<.0001) and performance status (p=.016). The most common margin for SRS
was 0 mm (49.1%; p=.0021). The most common dose constraints other than critical
structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most
common treatment modality (54.4%) and mono-isocenter technique for multiple brain
metastases was commonly used (43.9%; p=.23). Most departments do not have a policy
for brain metastases treatment (64.9%; p=.024).
Conclusions: This is one of the first national surveys assessing the use of SRS for brain
metastases in clinical practice. These data highlight some clinical considerations for
physicians treating brain metastases with SRS.
Summary: This is among the first national surveys to assess the use of SRS for brain
metastases in clinical practice. Specifically, radiation oncologist reported increasingly
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using SRS instead of WBRT for treating
<10 metastases, with the LINAC being
the most common modality. Further,
treatment parameters considered the
most important included 0 mm margins,
conformity index, brain V12, and monoisocenter technique for multiple brain
metastases. These results may provide
context regarding the use of SRS for brain
metastases in clinical practice.

Published by Jefferson Digital Commons, 2018

JHN JOURNAL

MATERIALS AND METHODS
Study Design
An 18 question, non-incentivized electronic survey was distributed to radiation
oncologists at National Cancer Institute
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designated cancer centers in the United
States (60). Centers without radiation
oncologists were excluded. The total
number of physicians contacted was 697.
Physicians who reported not prescribing
SRS were not invited to complete
remaining survey questions. Per institutional policy, this study was IRB-exempt.

number of lesions (p<.0001), histology
(p=.0014), performance status (p=.016)
and location (p<.0001) as determined by
sign-test. Leptomeningeal disease was
statistically significant versus all other
choices as the predominant contraindication to prescribing SRS without WBRT
(93%; CI [83-98%]).

Statistical Analysis

Treatment Modality and Planning

Depending on type of question, 95%
confidence interval (estimate of proportion), sign test (difference from expected
mean) or Chi-square test (difference
from expected distribution) were used
to determine if responses differed
significantly from random distribution.
All data analyses were completed using
Stata software and a P value<0.05 was
considered to be statistically significant.

LINAC (54.4%) was more commonly
used than the CyberKnife (14.0%) or
Gamma Knife (31.6%) for SRS treatment (p=.0009). The mono-isocenter
technique for multiple brain metastases
was commonly used (43.9%; p=.23). The
most common margin for SRS was 0 mm
(49.1%; p=.0021), with 38.6% and 12.3%
prescribing a 1 mm and 2 mm margin,
respectively. The most common dose
constraints other than critical structure
were conformity index (84.2%) and V12
(61.4%). Diameter, volume and histology
of lesion were all ranked as significant
in determining the SRS prescription
dose (sign-test, p<.0001, p=.001 and
p<.0001, respectively). Notably, most
departments do not have a policy in
place for treating brain metastases with
SRS (64.9%; p=.024).

five years. While the survey did not evaluate the role insurers play in physicians’
decision making, private insurance typically recognizes the role of SRS in treating
multiple brain metastases with no clear
maximum identified.18 Additionally, citing
a growing body of literature regarding
safety and efficacy, current National
Comprehensive Cancer Network (NCCN)
recommendations for SRS alone do not
specify a maximum number of lesions.19

RESULTS
Response and Demographic Data
All survey results are reproduced in
Table 1. Of 697 physicians surveyed, 118
(16.9%) responded, with 28.7% reporting
that they do not treat brain metastases
with SRS. Respondents represented 51
different institutions across 28 states
with varying years of practice experience.

Indications and Use in Practice
Respondents primarily treated CNS (66.2%,
95% CI [54-77%]); lung was numerically
the second most commonly treated
disease site (49.3%). SRS (73.7%) was
used more frequently than WBRT (10.5%)
for <10 brain metastases (p<.0001) while
WBRT (82.5%) was used more frequently
than SRS (5.3%) for >=10 brain metastases (p<.0001). The maximum number
of lesions physicians were willing to treat
with SRS without WBRT in the treatment
session was 1-4 (40.4%) and 5-10 (42.4%)
(p<.0001; compared to 11-15, 16-20 and
no limit). Most physicians reported they
would not treat more than 10 lesions
over multiple sessions with SRS (43.9%;
p=.0003) but 19.3% reported there was
no limit to the number they would treat.
Physicians indicated that their practice
had changed in the past 5 years by more
frequently using SRS without WBRT
(84.2%) and SRS without other treatments
(i.e. surgery or WBRT; 82.5%). Criteria used
to determine SRS versus WBRT use were
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DISCUSSION
Despite increasing use of SRS to treat
brain metastases, little exists in terms
of guidance for physicians using this
modality. Moreover, our data indicate that
most departments do not have policies
governing SRS use. Importantly, no clear
guidelines exist regarding the maximum
number of metastases for which SRS is
recommended, despite a historicallyused cutoff of 4 in clinical trials.5,13,14 In
this study, 42.4% of respondents reported
using SRS for patients with 5-10 metastases and 17.5% of respondents offering
it for more than 10 lesions without WBRT.
Thus, a significant number of respondents
are using SRS for more than the standard
4 lesions. In total, 73.7% of respondents
reported using SRS more often for <10
metastasis, and 82.5% used WBRT more
often for >10 lesions. These physicians
may be influenced by a shifting paradigm
towards SRS alone for a greater than 5
or greater than 10 lesions.15-17 Indeed,
the majority of respondents reported
increasing their use of SRS over the last

Knisely et al first examined the use of
SRS in clinical practice several years ago;
physicians at two conferences hosted by
national stereotactic radiosurgery societies were asked to fill a questionnaire,
with a majority of respondents considering it “reasonable” to treat greater
than 5 metastases with SRS alone.20
More recently, Sandler et al evaluated practicing physicians’ “cutoff” for
treating brain metastases with SRS alone
versus WBRT, among other scenarios.21
Importantly, they found CNS-specialists
to be comfortable treating a mean of
8.1 lesions compared to 5.6 and 5.1
lesions for low-volume CNS specialists
and non-CNS specialists respectively.21
While our survey did not stratify SRS use
according to specialization, our results
reflect a similar trend among physicians
at a national level for treating greater than
five lesions with SRS alone.
Notably, recent American Society for
Therapeutic Radiology and Oncology
(ASTRO) Choosing Wisely guidelines
recommend against using adjuvant
WBRT with SRS, and instead recommend SRS monotherapy for brain
metastases.12,22 However, no guidance is
provided regarding the SRS plan evaluation. The present study identifies several
parameters in current SRS use for brain
metastasis in practice, including the use
of 0 mm margins, conformity index, brain
V12, and the mono-isocenter technique
for multiple brain metastases. While our
survey did not specifically assess the
values used for each parameter, retrospective data indicate that V12 greater
than 10.9 cm3 is associated with a 51%
1 year risk of radionecrosis.23 Likewise,
other treatment parameters appear to
play an important role in the development
of a safe and effective treatment plan.
The overall response rate was low for
this study, introducing the potential for
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response bias. Despite this potential
limitation, emerging research suggests
that low response rates are not inherently associated with inaccurate results
or nonresponder bias.24,25 Moreover, the
wide geographic spread and distribution
of practice experience among respondents suggests that the current sample
was representative of the academic field
at large. As this survey was distributed to
physicians practicing at NCI-designated
cancer centers however, the responses
may not be reflective of the patterns
of SRS use in private practice. Another
potential limitation of the survey was
that it did not account for patient volume
per institution, which may be a surrogate
for expertise in SRS and could influence
aggressiveness in treating multiple brain
metastases. Furthermore, individual
practitioners were not asked about their
patient volumes, which may be a surrogate for clinical versus research time in an
academic setting and therefore influence
management preferences. Future studies
will be needed to continue to address
these issues and refine clinical practice.

CONCLUSIONS
To our knowledge, this is among the first
national assessments of the use of SRS
for brain metastases in clinical practice
in the U.S. The data indicate that radiation oncologists are increasingly using
SRS for the treatment of intracranial
lesions, even in situations which were
historically treated with WBRT. Treatment
parameters considered most by respondents include 0 mm margins, conformity
index, brain V12, and a mono-isocenter
technique for multiple brain metastases.
These data may reveal areas that require
guidance and instruction from cooperative group committees.
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